Mylan, Micro Labs Generics of Eliquis Approved by FDA

By Dave Sebastian

The Food and Drug Administration on Monday said it has approved two applications for the first generic version of the blood thinner Eliquis by Mylan NV's (MYL) Mylan Pharmaceuticals Inc. and Micro Labs Ltd.

The tablets, whose generic name is apixaban, prevent stroke in patients with nonvalvular atrial fibrillation and treats deep vein thrombosis and pulmonary embolism, the agency said.

Bristol-Myers Squibb Co. (BMY) makes Eliquis, whose sales rose 22% in the third quarter from the same period last year.

"These approvals mark the first generic approvals of a direct oral anticoagulant," Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in prepared remarks.

Bristol-Myers shares were down 0.2% at $63.39, while Mylan's stock was up 0.6% at $19.92 in afternoon trade.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

December 23, 2019 15:47 ET (20:47 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024